ERBB2 and breast cancer: In HER2+ breast cancer, DTCs expressing SOX2 and SOX9 can evade NK cell-mediated clearance by entering quiescence and downregulate cell surface-innate immune sensors, a phenomenon known as tumor dormancy (Malladi et al., 2016).